Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 134 (2), 113-20

Influenza Vaccine Administration in Rheumatoid Arthritis Patients Under Treatment With TNFalpha Blockers: Safety and Immunogenicity

Affiliations
Clinical Trial

Influenza Vaccine Administration in Rheumatoid Arthritis Patients Under Treatment With TNFalpha Blockers: Safety and Immunogenicity

S Salemi et al. Clin Immunol.

Abstract

Twenty-eight patients with low-moderate, stable rheumatoid arthritis (RA), under treatment with tumor necrosis factor (TNF) alpha blockers, were immunized at least once with non-adjuvanted trivalent influenza vaccine during three consecutive influenza seasons. Antibodies toward A influenza antigens significantly increased and reached protective levels, still detectable 6 months after vaccination, both in RA patients and healthy controls. Response to B antigen instead was only observed from the second year for healthy controls and in the third year for patients. No significant difference in disease activity and anti-nuclear antibodies was observed as a consequence of vaccine administration, whereas T regulatory cells showed a significant increase 30 days after immunization in RA patients. This study confirms safety of influenza vaccine administration in RA patients treated with TNFalpha blockers. The cohort follow-up revealed the overcoming of poor B vaccine antigen immunogenicity via repeated vaccinations. Finally, protective antibody response was still observed 6 months after vaccination.

Similar articles

See all similar articles

Cited by 29 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback